Maxpro Capital Acquisition (JMAC) Competitors $0.12 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends JMAC vs. AEZS, BMRA, CDIO, BFRI, HOTH, PRTG, GNPX, ORGS, ENSC, and ERNAShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Aeterna Zentaris (AEZS), Biomerica (BMRA), Cardio Diagnostics (CDIO), Biofrontera (BFRI), Hoth Therapeutics (HOTH), Portage Biotech (PRTG), Genprex (GNPX), Orgenesis (ORGS), Ensysce Biosciences (ENSC), and Eterna Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Aeterna Zentaris Biomerica Cardio Diagnostics Biofrontera Hoth Therapeutics Portage Biotech Genprex Orgenesis Ensysce Biosciences Eterna Therapeutics Aeterna Zentaris (NASDAQ:AEZS) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends. Do analysts rate AEZS or JMAC? Aeterna Zentaris presently has a consensus price target of $60.00, indicating a potential upside of 1,585.39%. Given Aeterna Zentaris' higher probable upside, equities research analysts plainly believe Aeterna Zentaris is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aeterna Zentaris 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do institutionals & insiders hold more shares of AEZS or JMAC? 0.7% of Aeterna Zentaris shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 0.1% of Aeterna Zentaris shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in AEZS or JMAC? Aeterna Zentaris received 419 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformAeterna ZentarisOutperform Votes41960.37% Underperform Votes27539.63% Maxpro Capital AcquisitionN/AN/A Which has more risk & volatility, AEZS or JMAC? Aeterna Zentaris has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Which has higher earnings & valuation, AEZS or JMAC? Maxpro Capital Acquisition has lower revenue, but higher earnings than Aeterna Zentaris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAeterna Zentaris$2.37M2.69-$16.55M-$14.86-0.24Maxpro Capital AcquisitionN/AN/AN/AN/AN/A Is AEZS or JMAC more profitable? Maxpro Capital Acquisition has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Maxpro Capital Acquisition's return on equity of 0.00% beat Aeterna Zentaris' return on equity.Company Net Margins Return on Equity Return on Assets Aeterna Zentaris-760.32% -83.45% -45.76% Maxpro Capital Acquisition N/A N/A N/A Does the media refer more to AEZS or JMAC? In the previous week, Aeterna Zentaris' average media sentiment score of 0.00 equaled Maxpro Capital Acquisition'saverage media sentiment score. Company Overall Sentiment Aeterna Zentaris Neutral Maxpro Capital Acquisition Neutral SummaryAeterna Zentaris and Maxpro Capital Acquisition tied by winning 5 of the 10 factors compared between the two stocks. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryUnclassified SectorNASDAQ ExchangeMarket Cap$1.60M$418.18M$111.45M$8.53BDividend YieldN/A8.07%N/A4.14%P/E RatioN/A9.049.1315.23Price / SalesN/A99.659.4797.74Price / CashN/A74.9595.6034.10Price / BookN/A74.19525.095.07Net IncomeN/A$31.01M$2.17M$225.46M7 Day Performance-12.63%-0.90%-0.65%0.37%1 Month Performance-18.49%-0.51%-0.23%3.57%1 Year Performance-84.13%11.58%15.41%29.43% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$0.12flatN/A-85.1%$1.60MN/A0.002,021High Trading VolumeAEZSAeterna ZentarisN/A$3.56+0.6%$60.00+1,585.4%-39.0%$6.38M$2.37M-0.2420Analyst ForecastGap UpBMRABiomerica0.9097 of 5 stars$0.37flatN/A-61.3%$6.26M$5.41M-1.0160Short Interest ↓News CoverageCDIOCardio Diagnostics3.2883 of 5 stars$0.26-7.1%$2.00+669.2%-17.1%$6.22M$20,000.000.007Gap UpHigh Trading VolumeBFRIBiofrontera2.2395 of 5 stars$1.09-11.4%$7.00+542.2%-76.9%$6.04M$34.07M-0.1870News CoverageGap DownHigh Trading VolumeHOTHHoth Therapeutics3.3034 of 5 stars$0.86+1.2%$3.50+307.0%-27.1%$5.87MN/A-0.534Gap UpPRTGPortage Biotech1.6611 of 5 stars$5.58-1.8%$120.00+2,050.5%-85.4%$5.86MN/A-0.126GNPXGenprex4.3389 of 5 stars$2.15-4.4%$10.00+365.1%-76.0%$5.82MN/A0.0020Short Interest ↑News CoverageORGSOrgenesis1.8506 of 5 stars$1.20flatN/AN/A$5.76M$530,000.000.00150Positive NewsGap UpENSCEnsysce Biosciences1.0309 of 5 stars$0.65+12.1%N/A-26.4%$5.73M$2.23M-0.2310Gap UpHigh Trading VolumeERNAEterna Therapeutics0.4079 of 5 stars$1.04-4.6%N/A-15.4%$5.63M$70,000.00-0.2410Short Interest ↑News Coverage Related Companies and Tools Related Companies AEZS Competitors BMRA Competitors CDIO Competitors BFRI Competitors HOTH Competitors PRTG Competitors GNPX Competitors ORGS Competitors ENSC Competitors ERNA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JMAC) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
